Karan Lal, DO, MS, FAAD

Lal emphasizes the dual approach of combining medical and cosmetic dermatology to effectively address skin issues like hyperpigmentation.

Renata Block, PA-C, and Karan Lal, DO, discuss the critical role of advanced practice providers in dermatology, the power of mentorship, and how collaborative learning improves patient outcomes.

Panelists discuss how research in pediatric psoriasis management needs more attention on long-term safety, treatment efficacy, and the psychosocial impact of the disease on young patients.

Panelists discuss how the two approved PDE4 inhibitors for pediatric plaque psoriasis differ in their systemic treatments, highlighting key differences in efficacy, safety profiles, and patient considerations for optimal use.

Panelists discuss how phosphodiesterase-4 (PDE4) inhibitors, with their ability to modulate inflammatory pathways, hold promise as therapeutic targets for immune-mediated diseases like pediatric plaque psoriasis, offering unique benefits by potentially reducing inflammation with a favorable safety profile for pediatric patients.

Panelists discuss how limited treatment options, safety concerns, adherence issues, and the lack of long-term data pose significant challenges in effectively managing pediatric vs adult plaque psoriasis, highlighting the need for more research and tailored approaches for this patient population.

Karan Lal, DO, and Helen T Shin, MD, discuss how early diagnosis of pediatric plaque psoriasis significantly improves management strategies and enhances long-term outcomes by allowing for timely intervention and personalized treatment plans.

Panelists discuss how managing psoriasis in children poses distinct challenges compared to adult patients.

Karan Lal, DO, and Helen T Shin, MD, discuss how diagnostic challenges in pediatric plaque psoriasis, such as its similarity to other skin conditions and potential underreporting, can complicate timely identification and appropriate management of the disease in children.

Karan Lal, DO, and Helen T Shin, MD, discuss how to address the psychosocial effects of plaque psoriasis on children and their families, exploring effective resources and interventions for support.

Panelists discuss how plaque psoriasis affects a significant number of children worldwide and can have substantial physical, emotional, and social impacts on young patients' quality of life and development.

Although acne is common for most people to experience in their lifetime, it is important to individualize treatment and provide appropriate care when working with a diverse patient base.

Karan Lal, DO, dives into the benefits of combination therapy for vitiligo with topicals and devices.

Karan Lal, DO, MS, FAAD, is a double-board certified pediatric and cosmetic dermatologist at Affiliated Dermatology in Scottsdale, Arizona.

The country's only double-board certified pediatric and cosmetic dermatologist shared what he learned from 5 unique patient cases this year.

In between sessions, Lal shared his favorite pearls from AAD, a recent challenging pediatric case in his practice, the significance of LinkedIn, and more.

An expert in dermatology reviews the case of a 10-year-old male with segmental vitiligo, shedding light on the panel's gaps in understanding this complex condition. The conversation explores the treatment challenges and the emotional impact on patients, particularly those of Asian or Indian descent.

Karan Lal DO, MS, FAAD presents the case of a 51-year-old African American male with vitiligo, exploring insurance challenges, treatment options such as topical ruxolitinib, Excimer, and phototherapy, and strategies for setting and managing patient treatment response expectations.

Dr Lal, an expert in dermatology, presents the case of a 45-year-old female with a history of childhood AD marked by severe symptoms. He recaps a panel conversation on the approach to treatment, emphasizing the importance of initiating effective and long-lasting treatment options for optimal relief.

Karan Lal, DO, MS, FAAD, discusses a case involving a 4-year-old male with atopic dermatitis, covering FDA-approved treatments for this age group, strategies for tapering and stopping treatment, the impact of the atopic march, and challenges with treatment prior authorizations.

Although rare, clinicians are encountering more pediatric patients who are at an increased risk of skin cancer due to immunosuppression.

Tips on growing your practice.